Tradipitant May Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia

According to interim analysis reported by Vanda Pharmaceuticals Inc, tradipitant -- a neurokinin-1 receptor (NK-1R) antagonist -- may accelerate clinical improvement in SARS-CoV-2 (COVID-19) pneumonia.